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We developed a two-site chemiluminescence immunoassay for human vascular endothelial growth factor (VEGF Moreover, the formationof new capillary blood vessels increases the opportunity for tumor cells to enter the circulation and permits metastasis [1, 2] . Clinical studies have shown that the intensity of the angiogenic response, measured by the degree of tumor microvascularization, correlated with poor prognosis in severaltypesof cancer, including breast [3] . A varietyof factors have been implicatedin the control of angiogenesis [4] . with placenta growth factor (PLGF) [8] . At least four isoforms of VEGF are generated by alternative splicingof a singlegene [9] . 2-(N-morpholino)ethanesulfonicacid (MES) buffer, pH 5.5, containing0.2molIL NaC1 (total volume of 540 j.tL). After 2 h of incubationat room temperature,the mixture was extensivelydialyzed against phosphate-buffered saline (PBS). mAbs were prepared according to standard procedures described previously [28] . BALB/c mice were obtained from Ciba-Geigy (Sisseln, Switzerland) and were kept according to federal guidelines (permit no. 117). Animals were injected with 35 j.g of conjugate, three times,at 3-week intervals. The immunogen was mixed in a 1:1 ratiowith TiterMax adjuvant (Vaxcel, Norcross,GA). Aftera restperiodof 6 months, mice were boosted intraperitoneally with 120 jg of conjugate, and fusionexperiments were performed 3 days later [28] . Chinchilla rabbits were injected subcutaneously with 130 j.tgof VEGF conjugate mixed with adjuvant(1:1ratio) and then furtherinjectedat 1-to 3-month intervals with 130 g of conjugatesupplemented with 50 tg of unconjugatedVEGF121. On the basis of published procedures [29] , the VEGF peptide 1-26 with a terminal cysteine(3 mg) was coupled to a KLH-bound 2-pyridyl disulfide group (10 mg) [30] . Rabbitswere immunized by repeatedinjections of 350 tg of the peptideconjugatemixed with adjuvant (1:1ratio).
Rabbit serafrom the animalsimmunized with VEGF121 were subjected to protein-G Sepharose column chromatography and the IgG fraction was elutedwith 0.1 mol/L glycine buffer, pH 2.7,whereas those animals immunized with the VEGF peptide were purified on a VEGF1_26 peptide-bound thiolpropyl-Sepharose column prepared according to the manufacturer's instructions. After extensivedialysis againstPBS, purifiedantibodies were stored at -40 #{176}C. mAbs were purified from hybridoma cell supematants by ammonium sulfate precipitation and protein G Sepharose chromatography. mAb puritywas assessed by sodium dodecyl sulfate-polyacrylamidegel electrophoresis (SDS-PAGE). Antibody concentrationwas determined by absorbance at 280 nm. In addition,each mAb was subjectedonce to amino acid analysis [26] . Antibody characteristics, namely the dissociationconstantof the antigen-antibodyequilibrium(Kd), and the cross-reactivity pattern,were determined by a modification of the competitive ELISA described previously [28] . Briefly, purified antibodies (10-700 tg/L) were incubated overnight at 4 #{176}C with increasingconcentrationsof VEGF calibrators or analogs. The antibody-antigen mixture was then transferred to VEGFcoated microtiter plates (0.01.tg/well). After 1 h of incubation at room temperature, binding of the antibody to the well was revealed by the addition of goat anti-mouse or anti-rabbit antibody conjugated to alkaline phosphatase, followed by substrate addition and A5 measurement. kDa) were obtained by running the gel electrophoresis in nonreduced (lanes [1] [2] [3] [4] [5] [6] and reduced conditions (lanes 7-13) as described previously (25] . Lanes Determined by competitive ELISA. b VEGF165 dimer and monomerwere obtained b y running the gel electrophoresis in nonreduced and reduced conditions, respectively (Fig. 2) .
conjugates made of human recombinant VEGFI2I, or a syntheticpeptide representing the VEGF N-terminal sequence 1-26 common to allVEGF isoforms.They were characterized by competitive ELISA (Fig. 1) and by Western blot analysis (Fig.2) .All the antibodiesrecognized both secretedisoforms, VEGF121 and VEGF165 ( Table 1 Likewise, all the antibodies raised against the VEGF whole molecule failed to recognize the VEGF N-terminal peptide 1-26. By Western blot experiments, they did not bind to the reduced and denatured monomers of VEGF, in contrastto the anti-peptide pAb 85568 (Fig.2 , Table 1 ), indicating that they recognized conformation-dependent epitopes.
Purified antibodies were labeled with acridinium ester and the bestcombination of antibodies for a sensitive two-site ICMA was determined by checkerboard analysis. Although combinations of two mAbs were possible, the optimal pair consisted of mAb 4299-1-21 as capture antibody bound to the microtiter plate, and pAb 85618 as acridinium-labeled tracer antibody. As expected from the crossreactivity pattern of the singleconstituents (Fig. 1) , the ICMA measured both secreted VEGF isoforms but not PLGF or PDGF-BB (the signal increase resulting from the addition of up to 1000 .tg/L of PLGF or PDGF-BB remained below 2 SD of the zero calibrator). Matrix effects on the ICMA performances were assessedby assaying tumor cytosolicextractsat various dilutions. As shown in Table 2 , both ovarian and breasttumor extracts were diluted in parallel with the calibrator.
Because VEGF binds to a2-macroglobulin [31] and to heparm [12] , we investigatedfor possibleinterferences by these molecules in the ICMA. As shown in to 101% (mean 91%, SD 9%) ( Table 4 breast and ovarian tumors as well as in normal breasttissues Because all the VEGF isoforms express identicalbiological (NAT and NDT) (Fig.4) . In 142 primary breast tumors, the activities, although differentially regulated through complex median VEGF concentration was 0.24 ng/mg total protein binding interactions with cellular components [12] , we consid-(range 0-12.3 ng/mg), whereas in 32 extractsof NAT, the ered it advantageous to measure VEGF in tumor samples with The mAbs that we developed showed high affinityfor detectedin 82% of ovarianand 67% of breasttumors, but only VEGF, with Kd valuesranging from 0.06 to 1.93 nmoVL. They in 19% of NAT. VEGF concentrations >0.5 ng/mg total compared favorably with the four mAbs developed against protein were measured in 47% of the ovarian and 36% of the VEGF165 by Kim et al. [33] , who reportedKd between 0.4 and breasttumors, in contrastto 6% of NAT only (seeDiscussion). [18] and by in situhybridization and immunohistochemistry [19] . Moreover, free-floating ascites tumor cells from ovarian malignancies expressed high amounts of VEGF both at the mRNA and the protein levels [18] . Significantly increasedVEGF concentrationswere measured in the ascitic fluid [23] and in the serum of patients with ovariancancer [24] , as compared with nonmalignant effusionsand normal serum. Additional evidence indicates that VEGF/VPF secretion by tumor cells may be an important mediator of ascites formation and maintenance [35] . VEGF concentrationin ovariantumors may thus well be an important indicatorof diseaseprogression.
nmoL/L. Of severalcombinations of mAbs and pAbs, we
In conclusion, the detection of substantial amounts of VEGF in two types of invasivetumors, compared with normal tissues, suggests that the assay should be a useful tool to further investigate the prognosticvalue of VEGF in breast and ovarian carcinomas, and to select patients for future anti-VEGF therapy.
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